ArticleJournal of Alzheimer's disease : JAD2025
Diagnostic journey and management of patients with mild cognitive impairment and Alzheimer's disease dementia: A multinational, real-world survey.
Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Efficacy of a language-concordant community health worker intervention to improve community-to-clinic linkage for dementia care: results of the randomized trial PLAN.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Enhancing Alzheimer's disease diagnosis in primary care through targeted screening of people at risk of developing dementia - study design and feasibility assessment of the PREDEM primary care study.Alzheimer's research & therapy · 2026Article
- Outcomes reported in interventional studies for mild cognitive impairment: a scoping umbrella review to inform core outcome set development.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Increase in healthcare utilization and Medicare payment with progression of preclinical Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
- Dementia diagnostic deserts: workforce and geographic inequities in the diagnostic pathway for cognitive impairment.Health affairs scholar · 2026Article
- Neuroimaging correlates and biomarker performance of a fully automated plasma p-tau217/Aβ42 ratio assay in a clinical cohort with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The diagnostic pathway of Alzheimer's disease in real-world clinical practice in Spain: results from the Adelphi Dementia Disease Specific Programme™.Frontiers in neurology · 2025Article
- Real-world diagnosis and management of mild cognitive impairment and Alzheimer's disease dementia in the United Kingdom.Journal of Alzheimer's disease reportsArticle
- Elecsys pT181p immunoassay: Clinical performance for ruling out amyloid pathology.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundAn Alzheimer's disease (AD) diagnosis made in the earliest symptomatic stages substantially benefits patients and their care partners. However, little is known regarding the clinical, healthcare system-level, and patient-specific barriers that hinder timely diagnosis and treatment.ObjectiveTo explore real-world practices surrounding the diagnostic journey and management of mild cognitive impairment (MCI)/AD dementia patients.MethodsData were drawn from Adelphi Real World Dementia Disease Specific Programme™, a cross-sectional survey of physicians treating MCI/AD dementia patients in France, Germany, Italy, Spain, the United Kingdom, the United States, and Japan between 2022 and 2024.ResultsOverall, 779 physicians reported data on 5551 patients. Physicians indicated current disease severity for 5421 patients; 37.2% had MCI (87.3% with suspected prodromal AD and 12.7% undetermined etiology), 17.2% AD with mild dementia, 31.1% AD with moderate dementia, and 14.5% AD with severe dementia. When not immediately diagnosed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.